DrugPatentWatch Database Preview
Acelrx Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for ACELRX PHARMS, and what generic alternatives to ACELRX PHARMS drugs are available?
ACELRX PHARMS has one approved drug.
There are seventeen US patents protecting ACELRX PHARMS drugs.
There are eighty-three patent family members on ACELRX PHARMS drugs in nineteen countries and six supplementary protection certificates in five countries.
Drugs and US Patents for Acelrx Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | 8,252,328 | Start Trial | Y | Start Trial | |||
Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | 8,778,394 | Start Trial | Start Trial | ||||
Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | 8,865,743 | Start Trial | Start Trial | ||||
Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | 9,744,129 | Start Trial | Y | Start Trial | |||
Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | 10,245,228 | Start Trial | Y | Start Trial | |||
Acelrx Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | 8,778,393 | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Acelrx Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2009536147 | Start Trial |
China | 101378732 | Start Trial |
Japan | 2014042845 | Start Trial |
Denmark | 2114383 | Start Trial |
South Korea | 20080084857 | Start Trial |
Germany | 602007007991 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Acelrx Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2114383 | 16C0010 | France | Start Trial | PRODUCT NAME: SUFENTANIL; REGISTRATION NO/DATE: EU/1/15/1042 20150918 |
2114383 | 300797 | Netherlands | Start Trial | PRODUCT NAME: SUFENTANIL, DESGEWENST IN DE VORM VAN SUFENTANILCITRAAT; REGISTRATION NO/DATE: EU/1/15/1042 20150922 |
2114383 | CR 2016 00007 | Denmark | Start Trial | PRODUCT NAME: SUFENTANIL; REG. NO/DATE: EU/1/15/1042/001-006 20150922 |
2114383 | 122016000023 | Germany | Start Trial | PRODUCT NAME: SUFENTANIL, WAHLWEISE IN FORM VON SUFENTANILCITRAT; REGISTRATION NO/DATE: EU/1/15/1042 20150918 |
2114383 | SPC/GB16/004 | United Kingdom | Start Trial | PRODUCT NAME: SUFENTANIL; REGISTERED: UK EU/1/15/1042 20150922 |
2114383 | CA 2016 00007 | Denmark | Start Trial | PRODUCT NAME: SUFENTANIL, HERUNDER SUFENTANIL SOM CITRAT; REG. NO/DATE: EU/1/15/1042/001-006 20150922 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.